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The emergence of new, more pathogenic viruses necessitates
elucidation of factors that promote viral evolution. Aging, a po-
tential factor, is associated with increased susceptibility to viral
infections. We used the enterovirus coxsackievirus B3 (CVB3) to
investigate the effects of host age on pathogenicity and viral gene
sequence. Old mice infected with a normally amyocarditic strain of
CVB3, CVB30, had significantly higher mean heart viral titers
compared with CVB30-infected adult mice. To determine whether
a change in the CVB30 viral population could contribute to the
higher titers observed in the old infected mice, CVB30 was passed
once through an old or adult host and the changes in pathogenicity
and viral genome were examined after subsequent infection of old
or adult mice. Adult mice infected with CVB30 that was passed
through an old host (CVB30Old) exhibited significantly higher
heart viral titers, pathology, and weight loss than adult mice
infected with either stock CVB30 or CVB30 passed through an
adult host (CVB30Adult). Sequence analysis of virus isolated from
CVB30Old-infected mice revealed 13 specific and reproducible
nucleotide changes. These changes result in a sequence that
matches the virulent CVB320 strain and are associated with
promoting cardiovirulence. In contrast, we observed only one
nucleotide change, low heart viral titers, and no heart and liver
pathology in adult mice infected with CVB30Adult. These results
demonstrate that the aged host promotes rapid selection of a
pathogenic variant of CVB3 from an avirulent strain and introduces
a host–virus paradigm for studies of viral infection in the aged.
aging  myocarditis  oxidative stress  pathology  viral selection
The emergence of new and more pathogenic viral diseases is adeveloping problem worldwide. Epidemiological, clinical, and
animal data demonstrate that aged hosts frequently have a higher
incidence, severity, and mortality from infections than adult hosts
(1–6). Current demographic data indicate that there are 400
million individuals worldwide over the age of 65 (7), and it is
projected that the elderly population will double by 2020 and more
than triple by 2050 (8). To date, this higher susceptibility of the aged
to viral diseases has been primarily attributed to the well described
age-associated dysregulation of the immune system (9–12), which,
in turn, can result in the aged host’s inability to mount an effective
immune response to viral pathogens. However, recent work has
demonstrated that other host factors, such as increased oxidative
stress or low antioxidant status, can promote the rapid evolution of
a virulent RNA viral species (13–17). Aging is associated with lower
antioxidant defenses and increases in oxidative stress (18). In-
creased oxidative stress has been demonstrated to promote viral
mutations in vitro and in vivo (13, 16, 19–21). Because of the current
global expansion in the elderly population, the potential for an aged
host to generate pathogenic viral strains may have significant public
health ramifications.
Coxsackieviruses are human enteroviruses, a group of pathogens
known to cause a wide variety of diseases, including the common
cold, hand-foot-and-mouth disease, encephalitis, and poliomyelitis
(22). Coxsackieviruses, particularly strain B3 (CVB3), can cause an
inflammation of the heart known as myocarditis and are believed
to be the causative agent of Keshan’s disease. CVB3 is primarily
known for its etiologic role in Keshan’s disease in children and
young adults (23), but previous work has demonstrated that cox-
sackieviruses also are found in older adults and are likely grossly
under diagnosed in this population (24, 25). In addition, coxsack-
ieviruses are known to cause pathology in humans in multiple other
organs (24, 26–31).
Myocarditis due to CVB3 infections has been associated with
the development of dilated cardiomyopathy, a common reason
for heart transplants (23). Previous work by Beck et al. (13, 32,
33) demonstrated that a normally amyocarditic CVB3, CVB30,
converts to a virulent and pathogenic species when passed
through an antioxidant-deficient host (selenium, vitamin E, or
glutathione peroxidase 1 knockout). This pathogenesis was
associated with viral genome changes matching sequences of a
virulent coxsackievirus strain, CVB320 (13, 32, 33). Because
aging is associated with elevated levels of oxidative stress, we
hypothesized that passage of CVB30 through an aged host
would promote rapid selection of a virulent viral species due to
changes in the viral genome. This phenomenon of rapid selection
in an aged host may contribute to the higher susceptibility,
morbidity, and mortality from viral infections in the elderly.
Results
Old Mice Infected with CVB30 Have Higher Viral Titers than CVB3
0-Infected Adult Mice. Adult (5 mo) and old (22 mo) C57BL6 male
mice were infected i.p. with the mild strain (CVB30), virulent
strain (CVB320), or media (control). At 10 days postinfection
(p.i.), the mice were killed and heart viral titers were evaluated. A
significantly greater number of CVB30-infected old mice (60%)
had detectable heart viral titers compared with CVB30-infected
adult mice (5%) (P  0.001). Furthermore, the mean of heart viral
titers was significantly higher in CVB30-infected old mice com-
pared with CVB30-infected adult mice (P  0.001) (Fig. 4, which
is published as supporting information on the PNAS web site).
Although adult mice infected with CVB320 had significantly
higher heart viral titers than CVB30-infected adult mice (P 
0.001), there was no significant difference between CVB30- and
CVB320-infected old mice (Fig. 4). No significant age differences
were observed in the incidence and severity of viral titers between
the CVB320-infected adult and old mice. No evidence of viral titer
was detected in the control mice.
Passage of the Mild CVB30 Virus Through Old Mice Results in a
Virulent Strain (CVB30Old) That Is Associated with High Mortality in
Recipient Mice. We performed a passage experiment to determine
whether the higher heart viral titers observed in the old, infected
mice were due to changes in the CVB30 genome. Groups of
seven adult C57BL6 mice were infected with stock CVB30 or
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CVB30 isolated from the hearts of previously infected old mice
(CVB30Old). During the 10-day infection period, mortality
occurred in 0% of the adult mice and 14% of the old mice
infected with CVB30. In contrast, 43% of the adult mice and
71% of the old mice infected with CVB30Old virus died during
the infection period. Thus, the passage of a mild CVB30 virus
through an old host produced a virus capable of causing mor-
tality in normally resistant adult hosts and significant mortality
in old recipient hosts (P  0.05) (Fig. 1A).
CVB30Old Infection Was Associated with Weight Loss, High Viral
Titers, and Pathology in Recipient Mice. Old mice infected with
CVB30 and adult and old mice infected with CVB30Old
suffered significantly greater percent weight loss than adult mice
infected with CVB30 (P  0.01) (Table 2, which is published as
supporting information on the PNAS web site). The weight loss
observed in mice infected with CVB30Old was similar to weight
loss observed by other investigators in mice after infection with
CVB3 Nancy, a well characterized virulent CVB3 strain (34).
As observed previously, heart viral titers in old mice infected with
CVB30 were significantly higher (1,000 fold higher, P  0.05)
than adult mice infected with CVB30 (Fig. 1B). Both adult and old
mice infected with CVB30Old had significantly higher heart viral
titers compared with adult and old mice infected with stock
CVB30 (P  0.05). However, there was no significant difference
between adult and old mice infected with CVB30Old (Fig. 1B). In
addition, a significantly greater percent of old CVB30-infected
mice (57%) and both adult and old CVB30Old-infected mice (86%
for each group) had detectable heart viral titers compared with
adult CVB30-infected mice (0%) (P  0.01).
There was little evidence of virus-induced myocarditis in the
CVB30-infected mice. This result was expected because CVB30
rarely causes myocarditis in healthy hosts (35), and C57BL6 mice
are typically resistant to its development (36). In contrast, we
observed significant myocarditis in adult mice infected with CVB3
0Old compared with mice infected with CVB30 (P  0.05) (Fig.
1C) (2). Heart pathology observed in adult mice infected with
CVB30Old was comparable with myocarditis observed after infec-
tion with the virulent CVB320 (Fig. 2) (37). We did not observe
significant myocarditis in old mice infected with CVB30Old (Fig.
1C), likely because the high mortality observed in this group (71%)
leads to only a few mice remaining by the peak day of heart
pathology around day 10 p.i. (Fig. 1A) (13).
In contrast, old mice infected with CVB30Old had significantly
greater liver pathology than both adult and old mice infected with
the stock CVB30 (P  0.05), likely contributing to the significantly
greater mortality rate in this group (Fig. 1D) (2). Adult CVB3
0Old-infected mice also tended to have greater liver pathology than
adult CVB30-infected mice (P  0.07) (Fig. 1D). We observed
evidence of viral infection in the livers of both adult and old
CVB30Old-infected mice, indicated by the presence of viral inclu-
sion bodies. These inclusion bodies also were observed in mice
infected with the virulent CVB320 virus (Fig. 2). Heart viral titer
and liver pathology were both inversely correlated with survival
[0.61 (P  0.01) and 0.81 (P  0.001), respectively], such that
the mice with the highest titers and pathology were less likely to
survive until the end of the infection period.
In contrast, the pancreas was equally affected by CVB30 and
CVB30Old infections, and there was no significant difference in
the viral titers or pathology between the infected groups. This
Fig. 1. Mice infected with CVB30Old suffered greater morbidity and mortality than mice infected with CVB30. Adult and old C57BL6 mice were infected with
CVB30 and compared with adult and old mice infected with CVB30 isolated from the ground heart supernatant of previously infected old mice (CVB30Old).
(A) Survival curves after CVB30 infection. Shown are results for adult mice infected with CVB30 (), old mice infected with CVB30 (‚), adult mice infected
with CVB30Old (■ ), and old mice infected with CVB30Old (Œ). Asterisks indicate significantly greater mortality than adult CVB30-infected mice (P  0.05 by
Kaplan–Meier survival plot analysis; n  7 per group). (B) Heart CVB3 titers (logarithm of TCID50 per gram of heart tissue) are expressed as mean  SEM as
previously described (54). Groups that do not share the same letter are significantly different at P  0.05 by Kruskal–Wallis one-way ANOVA (n  7 per group).
(C) Heart pathology. (D) Liver pathology. Pathology data shown as the percentage of organ cross-section area affected  SEM (n  7 per group). Groups not
sharing the same letter are significantly different at P  0.05.
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result was expected because the majority of CVB3 strains,
including the amyocarditic strain CVB30, spare the islets but
are virulent to the exocrine pancreas (Fig. 2) (34, 38, 39).
Upon initial necropsy, we observed hardened white foci through-
out the visceral adipose tissue in some of the old CVB30-infected
mice and adult and old CVB30Old-infected mice. Histological
evaluation revealed that these foci were areas of fat necrosis and
cellular infiltration. Previous investigators have reported that CVB3
can attack the adipose tissue in mice (34, 40). Fat necrosis lesions
were not observed as frequently in CVB30-infected mice (0%
adult, 29% old) as in CVB30Old-infected mice (29% adult, 71%
old) throughout the perirenal, periadrenal, and gonadal adipose
tissue. Histological analysis of the fat necrosis lesions demonstrated
that these lesions were similar to adipose pathology previously
observed in mice after infection with the virulent CVB320 (Fig. 2).
This experimental data support the hypothesis that single passage
of CVB30 through an old host results in formation of a pathogenic
viral strain associated with increased morbidity and mortality in
recipient hosts.
Increased Virulence of CVB30 After Passage Through an Aged Host Is
Associated with Specific Changes in the Viral Genome. We next
wanted to determine whether the increase in virulence after
passage of CVB30 through an old host was due to changes in the
viral genome. We sequenced regions of the genome associated with
virulence from virus isolated from the hearts of infected mice and
compared the results to the sequences of the well characterized
virulent CVB320 and avirulent CVB30 strains (13, 37, 41). Virus
isolated from both adult and old mice infected with CVB30Old had
13 specific nucleotide changes throughout the CVB3 genome
(Table 1; see also Fig. 5, which is published as supporting infor-
mation on the PNAS web site). Of the 13 total nucleotide changes
observed, 10 nucleotide changes were detected in the coding region,
of which 8 would code for different amino acids (Table 1). Six of
these nucleotide changes were previously shown by Beck et al. (13,
32) to differ under conditions of antioxidant deficiency (nucleotides
234, 788, 2271, 2438, 3324, and 7334) (Fig. 5). We observed seven
additional changes in the 5 nontranslated, viral capsid, and pro-
tease regions. These variations at nucleotides 598, 830, 987, 2632,
Fig. 2. Representative photomicrographs of heart, liver,
pancreas, and visceral adipose tissues from adult mice infected
with CVB30 or CVB30Old compared with those infected with
media (control) or CVB320 (positive control). Five-microgram
paraffin sections of heart, liver, and pancreas were stained
with hematoxylin and eosin. Arrowheads indicate lymphocyte
infiltration, arrows indicate viral inclusion bodies, and aster-
isks indicate intact islets of Langerhans. (Scale bars, 100 m;
Inset, 2 m.)
Table 1. Nucleotide and amino acid differences among the avirulent CVB30 strain, the known virulent CVB320
strain, and the CVB30 variants isolated after passage through adult or old mice
Nucleotide (5–3)
CVB3 Strain
Amino acid change Virus regionCVB30 CVB30Adult CVB30Old CVB320
234 C T T T — 5NTR
598 T T C C — 5NTR
788 G G A A Gly3Arg 1A
830 G G A A Val3Ile 1A
987 C C T T Ala3Val 1B
2271 A A T T Try3Phe 1C
2438 G G C C Glu3Gln 1C
2632 C C T T None 1D
2690 G G G A None 1D
2881 T T C C None 1D
3243 A A G G Gln3Arg 1D
3324 C C T T Ala3Val 2A
3434 G G A A Ala3Thr 2A
7334 C C T T — 3NTR
Nucleotides that are the same as those of the virulent CVB320 strain are shown in red. The input avirulent strain, CVB30, was
confirmed by sequencing. CVB30Adult refers to virus isolated from adult mice infected with CVB30Adult (n  3), and CVB30Old refers
to virus isolated from adult or old mice infected with CVB30Old (n  3 and 4, respectively). CVB320 was used as a virulent reference
strain. Virus regions 1A through 1D code for structural capsid proteins, and virus region 2A codes for a viral protease. —, not applicable.











2881, 3242, and 3434 would translate to amino acid modifications
that could affect CVB3 viral receptor binding andor virus assem-
bly (41).
Specifically, because of the observed mutation G3A at
nucleotide 830, we would expect an amino acid alteration at
position A30 (I3V) occurring in VP4, the smallest capsid
protein located in the viral interior (42, 43). The mutation C3T
at nucleotide 987 also would lead to an amino acid change at A82
(V3A), causing a conservative hydrophobic change in VP2. At
A566 in the capsid protein VP3, we would expect a modification
in amino acids (Q3E) due to the observed G3C mutation at
nucleotide 2438. A566 is five residues upstream of the putative
VP3VP1 cleavage site, where VP1 joins with the neighboring
protomer (37, 44). It has been proposed that the A566 position
in the canyon may be involved in receptor recognition or in a
neutralizing antibody-binding site (45).
All of the 13 nucleotide changes matched corresponding
nucleotides in the well characterized virulent CVB320 strain
(41) (Table 1). Thus, the increase in virulence after a single viral
passage through an old host ref lected specific nucleotide
changes in the CVB3 genome, previously demonstrated to be
important determinants of virulence and occurring during an-
tioxidant deficiency (37, 41, 46).
Rapid Viral Evolution Was Specific to the Old Host Environment and
Not Due to the Passage Through a C57BL6 Host in General. To
confirm that the observed rapid viral evolution was specific to
the old host environment, we compared the effect of passage of
CVB30 through old mice to the passage of CVB30 through
adult mice on the virulence, pathogenicity, and genome of
CVB30. A total of 20 adult mice (5 mo) were infected with 5 
105 tissue culture 50% infective dose (TCID50) CVB30 isolated
during peak viral titer production (day 3 p.i.) (23) from a
previously infected adult mouse (CVB30Adult) and compared
with the adult mice infected with either the stock CVB30 or
CVB30Old. CVB30Adult was isolated during peak viral titer
production to ensure a sufficient viral load to use for passage
studies. Unlike old mice, adult mice can effectively clear
CVB30 by day 10 p.i. during the peak development of myo-
carditis (Figs. 1 and 4) (13). However, we observed significant
nucleotide changes in the virus population as early as day 4 p.i.
in CVB30Old-infected mice (Table 1). After 10 days p.i., mice
were killed, and the tissues were collected aseptically for analysis.
In contrast to the 13 nucleotide changes observed in virus
isolated from CVB30Old-infected mice, only a single C3T muta-
tion at nucleotide 234 was observed in virus isolated from mice
infected with CVB30Adult (Table 1 and Fig. 5). This C3T change
at nucleotide 234 is observed in all naturally occurring CVB3 strains
(47) and was not sufficient to cause cardiovirulence in recipient
hosts. In contrast to 86% of CVB30Old infected mice, only 20% of
CVB30Adult-infected mice exhibited detectable heart viral titers
(P  0.01). CVB30Adult-infected mice also had significantly lower
heart viral titers (P  0.001) compared with those infected with
CVB30Old (Fig. 3A). In addition, mice infected with CVB30Adult
had significantly less myocarditis than those infected with CVB3
0Old (P  0.05) (Fig. 3B). These mice also exhibited lower liver viral
titers and pathology than those infected with CVB30Old, but these
differences did not reach statistical significance (data not shown).
These data suggest that the observed genome changes and the
associated increased virulence were not due to passage through a
C57BL6 host in general.
Discussion
Our results suggest that the single passage of a mild CVB3 strain
through an old host results in the rapid selection of a virulent CVB3
variant, which is associated with significantly increased heart viral
titers, pathology, weight loss, and death. It is well established that
the elderly frequently have a higher incidence and severity of, and
morbidity and mortality from, viral infections than adult hosts
(1–6). Currently, the increased susceptibility of the elderly to viral
infections has been primarily attributed to the well characterized
age-associated dysregulation of the immune system (9–12). How-
ever, recent work has demonstrated that other host factors, such as
increased oxidative stress or low antioxidant status, can promote the
rapid evolution of a virulent RNA viral species (13–17). Previous
work has demonstrated that a normally amyocarditic CVB3,
CVB30, converts to a virulent and pathogenic variant after
passage through an antioxidant-deficient host (selenium, vitamin E,
or glutathione peroxidase 1 knockout) (13, 32, 33). This pathogen-
esis was associated with viral genome changes matching sequences
of the virulent CVB320 strain (Table 1 and Fig. 5) (13, 32, 33).
Aging is associated with lower antioxidant defenses and increases
in oxidative stress (18). Therefore, we hypothesized that passage of
CVB30 through an aged host would generate a virulent viral
species due to changes in the viral genome (37). In general, old
CVB30-infected and CVB30Old-infected mice faired more poorly
during the course of infection than the adult mice. Of particular
interest is that adult mice infected with CVB30Adult had low heart
and liver pathology and low detectable viral titers. But adult mice
infected with CVB30Old suffered high mortality and percent
weight loss and significantly elevated viral titers and pathology that
were associated with significant changes in the CVB30 sequence.
We did not observe greater myocarditis in the old mice
infected with CVB30Old than old mice infected with stock
CVB30. But this is likely explained by the fact that the old mice
infected with CVB30Old had significantly greater liver pathol-
ogy than both adult and old mice infected with the stock CVB30
(P  0.05), and suffered from severe pancreas pathology and
significant percent weight loss (Table 2 and Fig. 2). In addition,
Fig. 3. Increased heart viral titer and pathology is specific to passage through
an aged host. C57BL6 mice were infected with CVB30 from various origins,
stock CVB30, CVB30 isolated from adult mice (CVB30Adult), and CVB30
isolated from old mice (CVB30Old) as described in Materials and Methods. (A)
Heart viral titer. Data shown are the mean logarithm of TCID50 per gram of
heart  SEM. (B) Heart pathology. Data shown are mean percentages of heart
area affected  SEM. The asterisk indicates that the value is significantly
higher than mice infected with CVB30 or CVB30Adult at P  0.001 and P 
0.05 for heart viral titer and pathology, respectively (Kruskal–Wallis one-way
ANOVA; n  7 per group for CVB30 and CVB30Old, and n  20 per group for
CVB30Adult).
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we observed that viral titer and liver pathology was significantly
positively correlated with mortality. It is well documented that
the development of myocarditis is delayed by a number of days
in comparison to peak viral titers (day 10 p.i. versus day 3–7 p.i.)
(13, 23). Old CVB30Old-infected mice started becoming mor-
ibund by day 4 p.i., and, by day 8 p.i., 71% of the mice had died
(Fig. 1 A). Therefore, it is likely that many of the old CVB3
0Old-infected mice succumbed to the infection before detectable
myocarditis developed.
It is important to note that these experiments were conducted
with a CVB30 viral strain that was directly originated from a
clone. Therefore, the stock CVB30 viral population used for
these experiments would be expected to be relatively homoge-
nous as opposed to a viral population that had undergone
multiple passages. What is intriguing in our experiment is that
the stock CVB30 was not passaged through old mice multiple
times before using it for infection studies; it was passaged only
once. Thus, the significant changes we observed in the sequence
and the associated increased morbidity and mortality in the
CVB30Old-infected mice occurred rapidly. In fact, we observed
the significant nucleotide base changes in some mice as early as
day 4 p.i (Table 1). It also is interesting to consider our data in
light of recent reports of reversion to virulence in poliovirus, a
related enterovirus, in individuals from resource-poor countries
receiving the live oral polio vaccine (48, 49). Further investiga-
tion is needed to determine whether this age-related phenom-
enon we observed is specific to CVB3 or whether it could occur
in other RNA viruses.
Although immune incompetence has been shown to influence
viral evolution (17, 50), it is unlikely that the nucleotide changes
observed after the single passage of CVB30 through old mice
are due to age-associated immune dysfunction alone. Previous
investigators have demonstrated that when CVB30 was passed
repeatedly through the immunodeficient SCID mice, the se-
quence analysis showed only the transition mutant, C3T, at
nucleotide 234 (Table 1 and Fig. 5) (35, 51). In addition, the aged
host is known to have elevated oxidative stress that is believed
to be a potential causative mechanism described by Beck et al.
(13, 33, 46) for the increased virulence of CVB30 in selenium-
and vitamin-E-deficient hosts. The aged mice we used were not
vitamin-E- or selenium-deficient. But we observed almost twice
the number of viral genome changes observed by Beck et al.,
including all of the changes they observed by passage through Se-
andor vitamin-E-deficient hosts. These findings suggest
that there may be additional mechanisms specific to the aged
influencing viral evolution not previously observed by other
researchers.
The observation that the environment of the aged host
transforms an avirulent CVB3 to a virulent and more pathogenic
species suggests a paradigm for explaining the higher suscepti-
bility of the aged to viral infection. This paradigm is further
supported by our previous observation in which we demon-
strated that old mice supplemented with 500 ppm of the anti-
oxidant vitamin E and exposed to influenza virus have signifi-
cantly lower lung viral titer compared with those consuming
adequate (30 ppm) vitamin E. Rhinoviruses, referred to as ‘‘the
common cold’’ virus, are in the same family as coxsackieviruses
and are known to cause greater morbidity in the elderly. In a
recent clinical study, we demonstrated that supplementing el-
derly subjects with the antioxidant, vitamin E significantly
reduces the risk of acquiring common cold in nursing home
residents (52).
Elevated oxidative stress has been shown to promote an
increase in RNA viral misinsertions (20, 21) and low antioxidant
status was shown to promote the generation of virulent CVB3
variants (13, 32, 33). Aging is associated with increased oxidative
stress and a dysregulated immune response (1, 18). We speculate
that these age-associated changes could promote viral evolution
by providing an environment characterized by dysfunctional
immune response incapable of controlling viral replication and
a higher level of potentially mutagenic oxidative stress, allowing
for the selection of CVB3 variants with increased virulence (Fig.
6, which is published as supporting information on the PNAS
web site).
In conclusion, we report that viral passage through an aged
host, but not an adult host, promotes the rapid selection of a
virulent CVB3 strain from an avirulent strain. This selection was
associated with specific and reproducible nucleotide changes
that are similar to the genotype of the well characterized virulent
coxsackievirus strain, CVB320 (37). Although the mechanism
of this observed phenomenon is yet undefined, our data intro-
duce a potential host–virus paradigm for future studies of viral
infections in the aged. In light of the increased emergence of
infectious diseases and the growing number of elderly world-
wide, it is intriguing to consider the potential impact of age-
associated viral evolution on public health, an issue that warrants
further investigation.
Materials and Methods
Virus. The CVB30 and CVB320 plasmids were provided by S.
Tracy and N. Chapman (both from University of Nebraska,
Omaha). The plasmids were transfected and propagated in HeLa
cells (American Type Culture Collection, Rockville, MD), which
were incubated at 37°C and 5% CO2 for 3 days or until cytopathic
effect was observed. The cells and supernatant were frozen and
thawed three times. Viral progeny were clarified by centrifuga-
tion at 3,000  g, and 500 l of supernatant was stored at 80°C.
CVB30Old and CVB30Adult were isolated from the ground
heart supernatant of CVB30-infected old or adult mice, re-
spectively, via three cycles of freezethawing and clarification via
centrifugation at 14,000  g for 20 min at 4°C. To track the
pattern of viral evolution in each infected host, viral preparations
isolated from individual mice were not pooled. For the CVB3
0Adult passage control experiment, virus was isolated from in-
fected adult mice during peak viremia (day 3 p.i.) (23), when
adult mice have higher titers that can be isolated for passage.
Determination of Virulence Phenotype in Mice. Specific pathogen-
free male C57BL6 mice were obtained from The Jackson
Laboratory (Bar Harbor, ME), used at the age of 5 mo (adult)
and 22 mo (old), and fed a standard chow ad libitum. Animal
protocols were approved by the Animal Care and Use Commit-
tee of the John Mayer U.S. Department of Agriculture Human
Nutrition Research Center on Aging at Tufts University. Mice
were infected by i.p. injection of 0.1 ml of 5  105 TCID50 of virus
diluted in EMEM or mock-infected with EMEM alone (negative
control). Mice were housed individually in microisolator cages in
a ventilated containment facility.
At day 10 after infection or earlier if moribund, mice were
subjected to CO2 narcosis. Serum was collected via cardiac
puncture and the heart, liver, and pancreas were excised asep-
tically. One half of an anatomically similar piece of each organ
was fixed in 4% buffered formalin, mounted in paraffin, and
sectioned in 5-m longitudinal sections through the center of the
organ. Slides were stained with hematoxylin and eosin and
examined under light microscopy. Histopathological semiquan-
titative analysis was performed by a blinded pathologist. For
each organ, the percent area of tissue pathology for the heart,
liver, and pancreas was calculated semiquantitatively by dividing
the area of injury by the total area of the organ, then converting
to a percentage. Injury area was assessed by histological markers
of CVB3 infection specific for each organ of interest. Heart
tissue was considered injured if there was significant presence of
myocarditis, including mononuclear cell infiltration and necrosis.
Liver tissue injury was scored based on the presence of necrosis
and viral inclusion bodies throughout the tissue, and pancreas











damage included exocrine periductal andor parenchymal infil-
tration, andor acinar cell vacuolation, necrosis, and atrophy.
Viral titers in the heart, liver, and pancreas were determined
by previously described methods (37) with modification. One
half of each organ was weighed and homogenized in 400 l
(heart and pancreas) or 800 l (liver) of supplemented EMEM
using a sterile glass mortar and pestle. The volume of media used
to grind the liver tissue was doubled to accommodate the larger
liver samples and reduce nonspecific cytopathic effect. After
centrifugation at 14,000  g to remove cellular debris, 100 l of
the supernatant was used to determine viral titers. Viral titers
were determined by using 96-well plates (Becton Dickinson,
Franklin Lakes, NJ) with 3  103 HeLa cells per well. Samples
were serially diluted in 10-fold increments to 108, added to the
appropriate wells, incubated at 37°C and 5% CO2 for 5 days, and
scored for the presence of complete cytopathic effect. Viral titer
calculations were determined according to the formula of Reed
and Muench (53) and expressed as the logarithm of TCID50 per
gram of tissue.
RT-PCR. Stock CVB30 and virus contained in the ground su-
pernatant from infected heart, liver, or pancreas was propagated
in HeLa cells, isolated via polyethylene glycol precipitation, and
viral RNA extraction was conducted after the method of Beck et
al. (13). Viral cDNA was synthesized from 0.5 g of viral RNA
by using a reverse transcription system (Promega, Madison, WI).
Specific primers and PCR conditions are described in refs. 13
and 54. PCR was conducted with AmpliTaq Gold with Gene
Amp (Applied Biosystems, Branchburg, NJ). PCR products were
separated by electrophoresis in a 1.5% (wtvol) agarose gel and
stained with ethidium bromide. The 1-kb DNA ladder marker
(Invitrogen, Carlsbad, CA) was used to verify the PCR products.
Viral cDNA Sequencing and Analysis. Automated sequencing was
performed on an Applied Biosystems 3100 Genetic Analyzer
using BigDye 3.1 dye terminator chemistry and run on a 50-cm
capillary. Sequence analysis was performed by using Wisconsin
software on SeqWeb 2.1 (Accelrys, San Diego, CA).
Statistical Analysis. Data were analyzed by ANOVA for effect of
infection and age followed by Fisher’s least significant difference
post hoc test for individual comparisons of percent weight
(SYSTAT 10.0; Systat, Evanston, IL). Significant incidence and
severity of viral titers and pathology was calculated by using the
Pearson 2 statistic with Fisher’s exact test (two-tailed) and a
Kruskal–Wallis one-way ANOVA, respectively. Pearson corre-
lations were used to determine associations between percent
weight change, viral titers, pathology, and survival time. Survival
time was analyzed by using Kaplan–Meier curves. Values are
expressed as the mean  SEM. A value of P  0.05 was
considered statistically significant.
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